"Intravitreal Injections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
| Descriptor ID |
D058449
|
| MeSH Number(s) |
E02.319.267.530.475.500
|
| Concept/Terms |
Intravitreal Injections- Intravitreal Injections
- Injection, Intravitreal
- Injections, Intravitreal
- Intravitreal Injection
|
Below are MeSH descriptors whose meaning is more general than "Intravitreal Injections".
Below are MeSH descriptors whose meaning is more specific than "Intravitreal Injections".
This graph shows the total number of publications written about "Intravitreal Injections" by people in this website by year, and whether "Intravitreal Injections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 6 | 6 |
| 2017 | 0 | 7 | 7 |
| 2018 | 0 | 4 | 4 |
| 2019 | 1 | 4 | 5 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intravitreal Injections" by people in Profiles.
-
Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data. Asia Pac J Ophthalmol (Phila). 2023 Mar-Apr 01; 12(2):168-183.
-
The 0.19-mg Fluocinolone Acetonide Implant for the Treatment of Diabetic Macular Edema: An Expert Consensus. Ophthalmic Surg Lasers Imaging Retina. 2023 03; 54(3):166-173.
-
Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol. 2022; 7(1):e000957.
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
-
Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Ophthalmology. 2022 06; 129(6):605-613.
-
Uptake and Distribution of Administered Bone Marrow Mesenchymal Stem Cell Extracellular Vesicles in Retina. Cells. 2021 03 25; 10(4).
-
Rates of RNFL Thinning in Patients with Suspected or Confirmed Glaucoma Receiving Unilateral Intravitreal Injections for Exudative AMD. Am J Ophthalmol. 2021 06; 226:206-216.
-
Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database. Ophthalmic Surg Lasers Imaging Retina. 2020 09 01; 51(9):486-493.
-
Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity. J AAPOS. 2020 06; 24(3):149.e1-149.e5.
-
Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency. Eur J Ophthalmol. 2021 Mar; 31(2):612-619.